# Liposome-Encapsulated Rutin Attenuates Cisplatin-Induced Ototoxicity via Suppression of P53-Associated Oxidative Injury

## TL;DR

Liposome-encapsulated rutin reduces cisplatin-induced hearing damage by lowering oxidative stress and cell death in the inner ear.

## Contribution

Liposome-encapsulated rutin is proposed as a novel therapeutic to mitigate cisplatin ototoxicity.

## Key findings

- Lip-Rutin significantly reduces oxidative stress and apoptosis in OC-1 cells exposed to cisplatin.
- In vivo studies confirm Lip-Rutin's protective effect against cisplatin-induced ototoxicity.
- Liposome encapsulation improves rutin delivery and efficacy in the inner ear.

## Abstract

Cisplatin (CDDP) is a widely used chemotherapeutic agent, but its clinical applications are constrained by ototoxic side effects. Currently, few effective strategies exist to prevent or mitigate CDDP-induced ototoxicity. Rutin is known for its cell-protective effects by reducing oxidative stress and inhibiting apoptosis. However, its limited water solubility and inefficient delivery to the inner ear pose substantial challenges. To address this, rutin is encapsulated in liposomes (Lip-Rutin) for nanoscale drug delivery, leveraging its antioxidant properties. Lip-Rutin markedly attenuates CDDP-induced oxidative stress damage and apoptosis, demonstrating a protective effect on OC-1 cells. The efficacy of Lip-Rutin in safeguarding against CDDP-induced ototoxicity is further validated through in vivo studies. Consequently, Lip-Rutin emerges as a promising novel therapeutic agent for combating CDDP-induced ototoxicity.